Skip to Main Content

rAgenda

NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer CareTM

Thursday, March 22, 2018

7:00 – 8:00 AM


Breakfast, Exhibits, and General Poster Session (Exhibition Hall)


8:15 – 8:25 AM

Welcome and Opening Remarks

Robert W. Carlson, MD
Chief Executive Officer
National Comprehensive Cancer Network

8:30 – 9:15 AM


New NCCN Guidelines®: Cancer in People Living with HIV

Gita Suneja, MD
Duke Cancer Institute


9:20 – 10:05 AM


New Therapies for Ovarian Cancer

Deborah K. Armstrong, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins


10:05 – 10:35 AM


Break, Exhibits, and General Poster Session (Exhibition Hall)


10:35 – 11:10 AM


Management of Chronic Myeloid Leukemia During Pregnancy

Ellin Berman, MD
Memorial Sloan Kettering Cancer Center


11:15 AM – 12:15 PM


NCCN Guidelines® Updates: Prostate Cancer and Prostate Cancer Early Detection

Reducing Harms and Increasing Benefits of Prostate Cancer Early Detection

Peter R. Carroll, MD, MPH
UCSF Helen Diller Family Comprehensive Cancer Center

New Approaches to the Management of Prostate Cancer

James L. Mohler, MD
Roswell Park Comprehensive Cancer Center

12:15 – 1:30 PM


Lunch, Exhibits, and General Poster Session (Exhibition Hall)


Lunch Symposium§ 12:25 – 1:25 PM

Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy

1:30 – 2:45 PM


NCCN Guidelines® Updates: Colon and Rectal Cancers

Management of Locoregional Rectal Cancer

Christopher G. Willett, MD
Duke Cancer Institute

Optimizing Adjuvant Therapy for Localized Colon Cancer

Axel Grothey, MD
Mayo Clinic Cancer Center

Treatment Selection in Advanced Colorectal Cancer

Alan P. Venook, MD
UCSF Helen Diller Family Comprehensive Cancer Center


2:45 – 3:10 PM


Break, Exhibits, and General Poster Session (Exhibition Hall)


3:10 – 3:55 PM


Updates to the Management of Kidney Cancer 

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center


4:00 – 4:45 PM


NCCN Guidelines® Updates: Management of Multiple Myeloma

Shaji K. Kumar, MD
Mayo Clinic Cancer Center


4:45 – 5:30 PM


Free Time


5:30 – 8:00 PM


Welcome Reception: 5:30 – 7:30 PM
(Exhibition Hall)

 
Kids' Fun Ni
ght! 5:30 – 8:00 PM
(Gatlin A1 & Gatlin A2)


 

Friday, March 23, 2018

6:45 – 7:45 AM

Breakfast Symposium§ 

Biosimilars in the Evolving Cancer Care Landscape:
Experts Address Current Questions, Controversies, and Impact on Clinical Practice
 
 

7:00 – 8:00 AM


Breakfast, Exhibits, and General Poster Session (Exhibition Hall)


8:00 – 9:00 AM


NCCN Keynote Session: Transforming Cancer Care in America

This keynote session will provide updates and perspectives on the continuously evolving and ongoing transformation of cancer care in America and will include the following presentations:

The CMS Oncology Care Model: Where We’ve Been, and Where We’re Going

Ron Kline, MD, FAAP
Medical Officer, Patient Care Models Group
Center for Medicare & Medicaid Innovation(CMMI), Centers for Medicare & Medicaid Services (CMS)

A Managed Care Perspective: Where We Are, and Where We Could Go

Lee N. Newcomer, MD, MHA
Former Senior Vice President, Oncology and Genetics, UnitedHealthcare

 

9:00 – 10:10 AM

 

 NCCN Roundtable Discussion:
Emerging Issues in Oncology – A Multidisciplinary Discussion on Delivering and Receiving Cancer Care in Value-Based Healthcare Models

 Moderator: Clifford Goodman, PhD, Senior Vice President, The Lewin Group

Panelists: Travis H. Bray, PhD, Founder, Hereditary Colon Cancer Foundation; Randy Burkholder, Vice President of Policy and Research, PhRMA; Ron Kline, MD, FAAP, Medical Officer, Patient Care Models Group; ‎Center for Medicare and Medicaid Innovation (CMMI), Centers for Medicare & Medicaid Services (CMS); Daniel P. Mirda, MD, President, Association of Northern California Oncologists (ANCO); Michael N. Neuss, MD, Chief Medical Officer, Vanderbilt-Ingram Cancer Center; Lee N. Newcomer, MD, MHA; Bhuvana Sagar, MD, National Medical Director, Cigna

This non-accredited roundtable will provide an opportunity for a varied group of stakeholders including
providers, payers, patient advocates, industry, and government to discuss delivering and receiving cancer care
within value-based healthcare models.

 Sponsored by AbbVie; Supported by an educational donation provided by Amgen;
Supported by Astellas; Supported by Eisai Inc.;
Supported by Janssen Pharmaceutical Companies of Johnson & Johnson;
This activity is supported by an educational grant from Lilly; Supported by Novartis;
This activity was made possible by Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.;
Supported by Seattle Genetics

10:10 – 10:35 AM


Break, Exhibits, and General Poster Session (Exhibition Hall)


10:35 – 11:10 AM


Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients with Cancer

Gerald Soff, MD
Memorial Sloan Kettering Cancer Center


11:15 AM – 12:15 PM



NCCN Guidelines®: Melanoma

New NCCN Guidelines®: Uveal Melanoma

Christopher A. Barker, MD

Memorial Sloan Kettering Cancer Center

Treatment of Recurrent or Progressive Distant Metastatic Melanoma

April K. Salama, MD
Duke Cancer Institute


12:15 – 1:30 PM

 

Lunch, Exhibits, and General Poster Session (Exhibition Hall)

Lunch Symposium§ 12:25 – 1:25 PM

Emerging Systemic Therapy Options in Advanced Hepatocellular Carcinoma 
 

1:30 – 2:45 PM


 NCCN Guidelines® Updates: Breast Cancer

Updates on HER2-Positive Breast Cancer Treatment

Sharon H. Giordano, MD, MPH
The University of Texas MD Anderson Cancer Center

New Developments in the Management of Triple Negative Breast Cancer

Anthony D. Elias, MD
University of Colorado Cancer Center

Treatment of Hormone-Sensitive Advanced Breast Cancer

William J. Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University


2:45 – 3:10 PM


Break, Exhibits, and General Poster Session (Exhibition Hall)


3:10 – 4:10 PM


NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™):
Adult Cancer Pain and Palliative Care


Maria Dans, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Robert A. Swarm, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

 

4:15 – 5:00 PM


The Role of Molecular Pathology in Glioma Staging and Treatment of Anaplastic Gliomas

Matthias Holdhoff, MD, PhD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins






 Saturday, March 24, 2018

7:00 – 8:00 AM


Breakfast (Gatlin Ballroom Foyer)


8:00 – 8:45 AM


NCCN Guidelines® Updates: Targeted Therapy for Patients with Metastatic Non-Small Cell Lung Cancer

Karen L. Reckamp, MD, MS
City of Hope Comprehensive Cancer Center


8:50 – 9:35 AM


New NCCN Guidelines®: Recognition and Management of Immunotherapy-Related Toxicity 

John A. Thompson, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance


9:40 – 10:25 AM


Head and Neck Cancers: The Advantages of Advanced Radiation Therapy and the Importance of Supportive Care

Sharon Spencer, MD
University of Alabama at Birmingham Comprehensive Cancer Center


10:25 – 10:40 AM


Break (Gatlin Ballroom Foyer)


10:40 – 11:25 AM


Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of
Acute Myeloid Leukemia

Martin S. Tallman, MD
Memorial Sloan Kettering Cancer Center


11:30 AM – 12:15 PM


Updates on Screening and Diagnosis of Hepatocellular Carcinoma 

Anne M. Covey, MD
Memorial Sloan Kettering Cancer Center

12:15 – 1:00 PM


Lunch (Gatlin Ballroom Foyer)


1:00 – 1:45 PM


Emerging Treatment Options for Ph-positive and Ph-negative Acute Lymphoblastic Leukemia 

Patrick A. Brown, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins


1:50 – 2:35 PM


CAR T Cells and Impact on Cancer Treatment: Lessons from Acute Lymphoblastic Leukemia

Bijal Shah, MD
Moffitt Cancer Center


2:40 – 3:25 PM


The Changing Treatment Landscape for Metastatic Urothelial Carcinoma

Thomas W. Flaig, MD
University of Colorado Cancer Center


3:25 – 3:30 PM


Closing Remarks

Gary J. Weyhmuller, MBA, SPHR
Executive Vice President/Chief Operating Officer
National Comprehensive Cancer Network

 

 

§ These sessions are open to all health care providers attending the conference; pre-registration is not required. CME/CNE/CPE available. These symposia are accredited and supported separately from all other educational sessions on this agenda. Seating is limited and on a first-come, first-seated basis. Learn more about the satellite symposia here.

Agenda is subject to change.

Top